Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fifth consecutive year for the certification inSingapore * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 1677

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inVietnam * High scores in values, ethics and integrity serve as a driver for a strong cor...

2022-01-20 08:00 5227

Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive approval for provisional registration inAustralia GAITHERSBURG, Md., Jan. 20, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for seri...

2022-01-20 07:29 1278

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA

Genesis Prize Chairman highlights immense role of Jewish scientists and doctors in combatting the pandemic: "A very proud moment for the entire Jewish community" JERUSALEM, Jan. 20, 2022 /PRNewswire/ -- Today, The Genesis Prize Foundation announced Dr.Albert Bourla, Chairman and CEO of Pfizer,...

2022-01-20 06:13 1739

Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy

WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on thein-vivo gene replacement thera...

2022-01-19 22:30 1671

Operation Smile Announces 10-Year Commitment to Transform the Lives of 1 Million Patients Globally

VIRGINIA BEACH, Va., Jan. 19, 2022 /PRNewswire/ -- Global nonprofit Operation Smile announced a 10-year commitment today to increase access to care for 1 million patients who need cleft care and other essential surgeries. Entering its 40th anniversary year, the organization will scale up its inve...

2022-01-19 21:36 1517

Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets

JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provin...

2022-01-19 20:30 1559

Peijia Medical Obtained Exclusive License for JenaValve's Trilogy TAVR System for Treating AR in the Greater China Region

SUZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and wil...

2022-01-19 20:00 3309

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is exp...

2022-01-19 20:00 1589

Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. * Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutati...

2022-01-19 19:49 1247

Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

LACHEN, Switzerland, Jan. 19, 2022 /PRNewswire/ -- The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management. The development of inhibitors to r...

2022-01-19 19:00 1660

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

HYDERABAD, India, Jan. 19, 2022 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development & Manufacturing Organization (CRO-CDMO), today announced the app...

2022-01-19 18:30 2342

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

Good news to patients with corneal blindness: MIOK Keratoprosthesis, the World's First Artificial Cornea of 100% Non-biological Materials has been approved for listing in China.

BEIJING, Jan. 19, 2022 /PRNewswire/ -- On December 7, 2021, MIOK Keratoprosthesis was approved for listing by NMPA, the Chinese agency for regulating drugs and medical devices. MIOK Keratoprosthesis is the world's first ever approved artificial cornea that requires no co-implantation of donor co...

2022-01-19 12:25 2477

Good news to patients with corneal blindness: MIOK Keratoprosthesis, the World's First Artificial Cornea of 100% Non-biological Materials has been approved for listing in China.

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company r...

2022-01-19 09:00 7881

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...

2022-01-19 08:30 1352

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

Transplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies

LOS ANGELES, Jan. 19, 2022 /PRNewswire/ -- Transplant Connect, the world's leading software provider for the donation and transplantation field, is pleased to announce an investment from InVita Healthcare Technologies. InVita provides leading chain of custody software for complex medical environm...

2022-01-19 08:28 1619

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner * Surviv...

2022-01-19 08:05 2796

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondyli...

2022-01-19 08:00 2685

CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world's largest organizations dedicated to diagnostics and laboratory informatics

· Combined group to enable better public health outcomes through innovation in diagnostics and laboratory informatics technology TUCSON, Arizona, Jan. 18, 2022 /PRNewswire/ -- CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Syst...

2022-01-18 22:00 1747

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...

2022-01-18 21:00 1337

1 ... 290 291 292293294 295 296 ... 578